Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immutep Ltd.

http://www.immutep.com

Latest From Immutep Ltd.

Finance Watch: US, Hong Kong IPOs Are Hot, But Sirnaomics Stays Private

Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.

Financing Innovation

ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations

Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.

ASCO ImmunoOncology

Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes

The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.

Tech Transfer Deals Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Immutep S.A.S.
    • Immutep GmbH
    • Immutep, U.S., Inc.
    • Prima BioMed Ltd.
UsernamePublicRestriction

Register